Clinical Trial Update: Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of carboplatin, eribulin mesylate, and E7449 in BRCA-related cancers in breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• E7449 (E7449)
• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Cancer of the Breast | Phase 1, Phase 2 | Status: WITHDRAWN